Nobutaka Fujii

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3672218/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chemokine SDF1 Mediated Bone Regeneration Using Biodegradable Poly(D,L-lactide- <i>co</i> -glycolide) 3D Scaffolds and Bone Marrow-Derived Mesenchymal Stem Cells: Implication for the Development of an "Off-the-Shelf―Pharmacologically Active Construct. Biomacromolecules, 2020, 21, 4888-4903.	5.4	6
2	Peripheral administration of SB223412, a selective neurokinin-3 receptor antagonist, suppresses pulsatile luteinizing hormone secretion by acting on the gonadotropin-releasing hormone pulse generator in estrogen-treated ovariectomized female goats. Journal of Reproduction and Development, 2020, 66, 351-357.	1.4	8
3	Development of Mirror-Image Screening Systems for XIAP BIR3 Domain Inhibitors. Bioconjugate Chemistry, 2019, 30, 1395-1404.	3.6	10
4	Synthesis of jaspine B regioisomers through palladium-catalyzed stereoselective tetrahydrofuran formation: Insight into the ligand recognition of sphingosine kinases. Tetrahedron, 2018, 74, 1802-1809.	1.9	7
5	Structure–Activity Relationship Study of Cyclic Pentapeptide Ligands for Atypical Chemokine Receptor 3 (ACKR3). Journal of Medicinal Chemistry, 2018, 61, 3745-3751.	6.4	3
6	Head-to-tail macrocyclization of cysteine-free peptides using an o -aminoanilide linker. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1283-1286.	2.2	15
7	Inhibition of stromal cell–derived factor-1α/CXCR4 signaling restores the blood-retina barrier in pericyte-deficient mouse retinas. JCI Insight, 2018, 3, .	5.0	8
8	Identification of selective inhibitors of sphingosine kinases 1 and 2 through a structure–activity relationship study of 4-epi-jaspine B. Bioorganic and Medicinal Chemistry, 2017, 25, 3046-3052.	3.0	11
9	Synthesis of Grb2 SH2 Domain Proteins for Mirror-Image Screening Systems. Bioconjugate Chemistry, 2017, 28, 609-619.	3.6	16
10	Fe(<scp>ii</scp>)-Complexation of tripodal hexapeptide ligands with three bidentate triazolylpyridines: induction of metal-centred chirality by peptide macrocyclization. Dalton Transactions, 2017, 46, 13673-13676.	3.3	4
11	Synthesis of the Src SH2 domain and its application in bioassays for mirror-image screening. RSC Advances, 2017, 7, 38725-38732.	3.6	6
12	Investigation of the inhibitory mechanism of apomorphine against MDM2–p53 interaction. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2571-2574.	2.2	8
13	A Novel Peptide Derived from the Fusion Protein Heptad Repeat Inhibits Replication of Subacute Sclerosing Panencephalitis Virus In Vitro and In Vivo. PLoS ONE, 2016, 11, e0162823.	2.5	11
14	Neuropeptide derivatives to regulate the reproductive axis: Kisspeptin receptor (KISS1R) ligands and neurokininâ€3 receptor (NK3R) ligands. Biopolymers, 2016, 106, 588-597.	2.4	2
15	Total synthesis of odoamide, a novel cyclic depsipeptide, from an Okinawan marine cyanobacterium. Organic and Biomolecular Chemistry, 2016, 14, 9093-9104.	2.8	22
16	Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. Retrovirology, 2016, 13, 70.	2.0	10
17	Novel 3,4,7-Substituted Benzofuran Derivatives Having Binding Affinity to κ-Opioid Receptor. Chemical and Pharmaceutical Bulletin, 2016, 64, 996-1003.	1.3	2
18	Functional 1,3a,6a-triazapentalene scaffold: Design of fluorescent probes for kinesin spindle protein (KSP). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5765-5769.	2.2	21

#	Article	IF	CITATIONS
19	Screening of a virtual mirror-image library of natural products. Chemical Communications, 2016, 52, 7656.	4.1	18
20	Structure–activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 1136-1141.	3.0	25
21	Formal Total Synthesis of (±)-Strictamine Based on a Gold-Catalyzed Cyclization. Organic Letters, 2016, 18, 1670-1673.	4.6	59
22	A Novel KSP Inhibitor, KPYB10602, Induces Mitotic Arrest and Cell Death in Breast Cancer Cells. Journal of St Marianna University, 2016, 7, 105-116.	0.1	1
23	Anti-HIV-1 activity determined by Î ² -galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method. Antiviral Chemistry and Chemotherapy, 2015, 24, 77-82.	0.6	3
24	Gold atalyzed Cascade Cyclization of 2â€Alkynylâ€≺i>Nâ€Propargylanilines by Rearrangement of a Propargyl Group. Angewandte Chemie, 2015, 127, 7973-7977.	2.0	16
25	Goldâ€Catalyzed Cascade Cyclization of 2â€Alkynylâ€∢i>Nâ€Propargylanilines by Rearrangement of a Propargyl Group. Angewandte Chemie - International Edition, 2015, 54, 7862-7866.	13.8	65
26	Structure–activity relationship study on senktide for development of novel potent neurokinin-3 receptor selective agonists. MedChemComm, 2015, 6, 469-476.	3.4	6
27	Development of Novel CXC Chemokine Receptor 7 (CXCR7) Ligands: Selectivity Switch from CXCR4 Antagonists with a Cyclic Pentapeptide Scaffold. Journal of Medicinal Chemistry, 2015, 58, 5218-5225.	6.4	19
28	Convenient synthesis of spiroindole derivatives via palladium-catalyzed cyclization of propargyl chlorides. Tetrahedron, 2015, 71, 6580-6585.	1.9	6
29	Synthesis of Fused Carbazoles by Gold-Catalyzed Tricyclization of Conjugated Diynes via Rearrangement of an <i>N</i> -Propargyl Group. Organic Letters, 2015, 17, 6250-6253.	4.6	41
30	Investigations of possible prodrug structures for 2-(2-mercaptophenyl)tetrahydropyrimidines: reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds. Organic and Biomolecular Chemistry, 2015, 13, 4706-4713.	2.8	14
31	Identification of anti-HIV agents with a novel benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold. Bioorganic and Medicinal Chemistry, 2015, 23, 1447-1452.	3.0	19
32	Mode of Binding of the Cyclic Agonist Peptide TC14012 to CXCR7: Identification of Receptor and Compound Determinants. Biochemistry, 2015, 54, 1505-1515.	2.5	19
33	Dual Gold Catalysis: A Novel Synthesis of Bicyclic and Tricyclic Pyrroles from <i>N</i> -Propargyl Ynamides. Organic Letters, 2015, 17, 604-607.	4.6	132
34	A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Experimental Hematology, 2015, 43, 404-413.e5.	0.4	4
35	Potential new chemotherapy strategy for human ovarian carcinoma with a novel KSP inhibitor. Biochemical and Biophysical Research Communications, 2015, 463, 222-228.	2.1	5
36	Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread. Virology, 2015, 484, 364-376.	2.4	9

#	Article	IF	CITATIONS
37	Design, synthesis, and structure–activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 1776-1787.	3.0	24
38	Direct Construction of Fused Indoles by Gold-Catalyzed Cascade Cyclization of Conjugated Diynes. Organic Letters, 2015, 17, 1774-1777.	4.6	44
39	Synthesis and biological evaluation of the [d-MeAla11]-epimer of coibamide A. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 302-306.	2.2	18
40	Formal [4+2] Reaction between 1,3â€Diynes and Pyrroles: Gold(I)â€Catalyzed Indole Synthesis by Double Hydroarylation. Chemistry - A European Journal, 2015, 21, 1463-1467.	3.3	91
41	Synthesis of fused tetracyclic spiroindoles via palladium-catalysed cascade cyclisation. Chemical Communications, 2014, 50, 298-300.	4.1	38
42	Design and synthesis of fluorescent probes for GPR54. Bioorganic and Medicinal Chemistry, 2014, 22, 3325-3330.	3.0	7
43	Optimization of diaryl amine derivatives as kinesin spindle protein inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 3171-3179.	3.0	7
44	Gold-Catalyzed Cascade Cyclization of (Azido)ynamides: An Efficient Strategy for the Construction of Indoloquinolines. Organic Letters, 2014, 16, 3138-3141.	4.6	127
45	Dual Gold Catalysis: Synthesis of Polycyclic Compounds via Cĩ£¿H Insertion of Gold Vinylidenes. Chemistry - A European Journal, 2014, 20, 16331-16336.	3.3	69
46	Development of Novel Neurokinin 3 Receptor (NK3R) Selective Agonists with Resistance to Proteolytic Degradation. Journal of Medicinal Chemistry, 2014, 57, 8646-8651.	6.4	20
47	Synthesis of IB-01212 by multiple N-methylations of peptide bonds. Bioorganic and Medicinal Chemistry, 2014, 22, 6156-6162.	3.0	14
48	Kinesin Spindle Protein Inhibitors with Diaryl Amine Scaffolds: Crystal Packing Analysis for Improved Aqueous Solubility. ACS Medicinal Chemistry Letters, 2014, 5, 566-571.	2.8	19
49	A radiogallium–DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1386-1388.	2.2	5
50	Structure–activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4557-4561.	2.2	22
51	Design and synthesis of biotin- or alkyne-conjugated photoaffinity probes for studying the target molecules of PD 404182. Bioorganic and Medicinal Chemistry, 2013, 21, 2079-2087.	3.0	14
52	Structure–activity relationship study of tachykinin peptides for the development of novel neurokinin-3 receptor selective agonists. Bioorganic and Medicinal Chemistry, 2013, 21, 2413-2417.	3.0	6
53	Characterization of the receptor binding residues of kisspeptins by positional scanning using peptide photoaffinity probes. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2628-2631.	2.2	9
54	Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. International Journal of Biochemistry and Cell Biology, 2013, 45, 908-915.	2.8	6

#	Article	IF	CITATIONS
55	Diversity-oriented synthesis of pyrazolo[4,3-b]indoles by gold-catalysed three-component annulation: application to the development of a new class of CK2 inhibitors. Organic and Biomolecular Chemistry, 2013, 11, 3288.	2.8	20
56	Synthesis of pachastrissamine (jaspine B) and its derivatives by the late-stage introduction of the C-2 alkyl side-chains using olefin cross metathesis. Tetrahedron, 2013, 69, 4211-4220.	1.9	26
57	Synthesis and functional analysis of deferriferrichrysin derivatives: Application to colorimetric pH indicators. Bioorganic and Medicinal Chemistry, 2013, 21, 4296-4300.	3.0	3
58	Convergent Synthesis of (â^')â€Quinocarcin Based on the Combination of Sonogashira Coupling and Gold(I)â€Catalyzed 6â€ <i>endo</i> â€ <i>dig</i> Hydroamination. Chemistry - A European Journal, 2013, 19, 8875-8883.	3.3	24
59	Palladium-Catalyzed Medium-Ring Formation for Construction of the Core Structure of <i>Laurencia</i> Oxacycles: Synthetic Study of Laurendecumallene B. Organic Letters, 2013, 15, 3046-3049.	4.6	10
60	Affinity-based screening of MDM2/MDMX–p53 interaction inhibitors by chemical array: Identification of novel peptidic inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3802-3805.	2.2	24
61	HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 4035-4038.	3.2	6
62	Development and application of fluorescent SDF-1 derivatives. Future Medicinal Chemistry, 2012, 4, 837-844.	2.3	4
63	Gold(I)-Catalyzed Regioselective Inter-/Intramolecular Addition Cascade of Di- and Triynes for Direct Construction of Substituted Naphthalenes. Journal of Organic Chemistry, 2012, 77, 4907-4916.	3.2	83
64	Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4). Organic and Biomolecular Chemistry, 2012, 10, 5720.	2.8	32
65	CXCR4 Stimulates Macropinocytosis: Implications for Cellular Uptake of Arginine-Rich Cell-Penetrating Peptides and HIV. Chemistry and Biology, 2012, 19, 1437-1446.	6.0	103
66	Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016. FEBS Letters, 2012, 586, 3639-3644.	2.8	22
67	Lewis-acid-mediated ring-exchange reaction of dihydrobenzofurans and its application to the formal total synthesis of (â^)-quinocarcinamide. Tetrahedron Letters, 2012, 53, 6273-6276.	1.4	7
68	Gold-Catalyzed Three-Component Annulation: Efficient Synthesis of Highly Functionalized Dihydropyrazoles from Alkynes, Hydrazines, and Aldehydes or Ketones. Organic Letters, 2012, 14, 326-329.	4.6	70
69	A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats. Biochemical and Biophysical Research Communications, 2012, 424, 257-261.	2.1	9
70	Total Synthesis of (â^)â€Quinocarcin by Gold(I)â€Catalyzed Regioselective Hydroamination. Angewandte Chemie - International Edition, 2012, 51, 9169-9172.	13.8	63
71	Paradoxical Downregulation of CXC Chemokine Receptor 4 Induced by Polyphemusin II-Derived Antagonists. Bioconjugate Chemistry, 2012, 23, 1259-1265.	3.6	7
72	Structure–Activity Relationship Study of a CXC Chemokine Receptor Type 4 Antagonist, FC131, Using a Series of Alkene Dipeptide Isosteres. Journal of Medicinal Chemistry, 2012, 55, 2746-2757.	6.4	36

#	Article	IF	CITATIONS
73	Structure–activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents. Bioorganic and Medicinal Chemistry, 2012, 20, 6434-6441.	3.0	25
74	Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles. Organic and Biomolecular Chemistry, 2012, 10, 6792.	2.8	24
75	Structure-Based Design of Novel Potent Protein Kinase CK2 (CK2) Inhibitors with Phenyl-azole Scaffolds. Journal of Medicinal Chemistry, 2012, 55, 2899-2903.	6.4	59
76	Double CH Functionalization in Sequential Order: Direct Synthesis of Polycyclic Compounds by a Palladium atalyzed CH Alkenylation–Arylation Cascade. Chemistry - A European Journal, 2012, 18, 5352-5360.	3.3	33
77	Design and synthesis of a novel class of CK2 inhibitors: application of copper- and gold-catalysed cascade reactions for fused nitrogen heterocycles. Organic and Biomolecular Chemistry, 2012, 10, 4907.	2.8	25
78	Synthesis and application of an Nδ-acetyl-Nδ-hydroxyornithine analog: Identification of novel metal complexes of deferriferrichrysin. Bioorganic and Medicinal Chemistry, 2012, 20, 2651-2655.	3.0	5
79	Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4–FC131 interactions. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2146-2150.	2.2	36
80	Efficient synthesis of aminomethylated azaindoles and corresponding pyrrole-fused derivatives by copper-catalyzed domino multicomponent coupling and cyclization. Tetrahedron, 2012, 68, 1695-1703.	1.9	13
81	Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 99-109.	1.0	23
82	Synthesis and Evaluation of a Bimodal CXCR4 Antagonistic Peptide. Bioconjugate Chemistry, 2011, 22, 859-864.	3.6	59
83	Potent CXCR4 Antagonists Containing Amidine Type Peptide Bond Isosteres. ACS Medicinal Chemistry Letters, 2011, 2, 477-480.	2.8	33
84	Activation of Neuropeptide FF Receptors by Kisspeptin Receptor Ligands. ACS Medicinal Chemistry Letters, 2011, 2, 53-57.	2.8	73
85	Design and synthesis of amidine-type peptide bond isosteres: application of nitrile oxide derivatives as active ester equivalents in peptide and peptidomimetics synthesis. Organic and Biomolecular Chemistry, 2011, 9, 3421.	2.8	18
86	Gold(I)-Catalyzed Polycyclizations of Polyenyne-Type Anilines Based on Hydroamination and Consecutive Hydroarylation Cascade. Journal of Organic Chemistry, 2011, 76, 9068-9080.	3.2	95
87	Structure–Activity Relationships of Carboline and Carbazole Derivatives as a Novel Class of ATP-Competitive Kinesin Spindle Protein Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 4839-4846.	6.4	73
88	Pachastrissamine (jaspine B) and its stereoisomers inhibit sphingosine kinases and atypical protein kinase C. Bioorganic and Medicinal Chemistry, 2011, 19, 5402-5408.	3.0	50
89	Direct Synthesis of Fused Indoles by Gold-Catalyzed Cascade Cyclization of Diynes. Journal of Organic Chemistry, 2011, 76, 1212-1227.	3.2	165
90	Concise site-specific synthesis of DTPA–peptide conjugates: Application to imaging probes for the chemokine receptor CXCR4. Bioorganic and Medicinal Chemistry, 2011, 19, 3216-3220.	3.0	12

#	Article	IF	CITATIONS
91	Direct synthesis of highly fused perimidines by copper(I)-catalyzed hydroamination of 2-ethynylbenzaldehydes. Tetrahedron, 2011, 67, 5168-5175.	1.9	29
92	The increase in surface CXCR4 expression on lung extravascular neutrophils and its effects on neutrophils during endotoxin-induced lung injury. Cellular and Molecular Immunology, 2011, 8, 305-314.	10.5	74
93	Kisspeptin neurons mediate reflex ovulation in the musk shrew (<i>Suncus murinus</i>). Proceedings of the United States of America, 2011, 108, 17527-17532.	7.1	69
94	Thioredoxin-interacting protein suppresses bladder carcinogenesis. Carcinogenesis, 2011, 32, 1459-1466.	2.8	65
95	Potent Anti-HIV-1 Activity of N-HR-Derived Peptides Including a Deep Pocket-Forming Region without Antagonistic Effects on T-20. Antiviral Chemistry and Chemotherapy, 2011, 22, 51-55.	0.6	3
96	Fluorescent imaging of highâ€grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. International Journal of Cancer, 2010, 127, 1180-1187.	5.1	37
97	Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood, 2010, 116, 5306-5315.	1.4	46
98	Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. Antiviral Research, 2010, 87, 179-186.	4.1	17
99	Gold atalyzed Intramolecular Alkyne Cycloisomerization Cascade: Direct Synthesis of Arylâ€Annulated[<i>a</i>]carbazoles from Anilineâ€Substituted Diethynylarenes. Advanced Synthesis and Catalysis, 2010, 352, 368-372.	4.3	127
100	Synthesis of Fused and Linked Bicyclic Nitrogen Heterocycles by Palladium atalyzed Domino Cyclization of Propargyl Bromides. Chemistry - A European Journal, 2010, 16, 8410-8418.	3.3	22
101	Induction of myogenic differentiation by SDFâ€1 via CXCR4 and CXCR7 receptors. Muscle and Nerve, 2010, 41, 828-835.	2.2	40
102	Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion Inhibitors. Journal of Biological Chemistry, 2010, 285, 39471-39480.	3.4	37
103	The Peptidomimetic CXCR4 Antagonist TC14012 Recruits β-Arrestin to CXCR7. Journal of Biological Chemistry, 2010, 285, 37939-37943.	3.4	77
104	Stereoselective Divergent Synthesis of Four Diastereomers of Pachastrissamine (Jaspine B). Journal of Organic Chemistry, 2010, 75, 3843-3846.	3.2	52
105	Ring-Construction/Stereoselective Functionalization Cascade: Total Synthesis of Pachastrissamine (Jaspine B) through Palladium-Catalyzed Bis-cyclization of Propargyl Chlorides and Carbonates. Journal of Organic Chemistry, 2010, 75, 3831-3842.	3.2	59
106	Efficient Synthesis of Pyrimido[1,2- <i>c</i>] [1,3]benzothiazin-6-imines and Related Tricyclic Heterocycles by S _N Ar-Type Câ^'S, Câ^'N, or Câ^'O Bond Formation with Heterocumulenes. Journal of Organic Chemistry, 2010, 75, 265-268.	3.2	34
107	Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. Organic and Biomolecular Chemistry, 2010, 8, 616-621.	2.8	71
108	Kinesin Spindle Protein (KSP) Inhibitors with 2,3-Fused Indole Scaffolds. Journal of Medicinal Chemistry, 2010, 53, 5054-5058.	6.4	49

#	Article	IF	CITATIONS
109	Construction of Linked Nitrogen Heterocycles by Palladium(0)-Catalyzed Intramolecular Domino Cyclization of 2-Alkynylaziridines Bearing a 2-Aminoethyl Group via Ring Expansion with Isocyanate. Journal of Organic Chemistry, 2010, 75, 3396-3400.	3.2	29
110	Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants. MedChemComm, 2010, 1, 276.	3.4	3
111	SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide. Antimicrobial Agents and Chemotherapy, 2009, 53, 1013-1018.	3.2	82
112	Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20*. Journal of Biological Chemistry, 2009, 284, 4914-4920.	3.4	41
113	Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Seminars in Cancer Biology, 2009, 19, 123-134.	9.6	29
114	Antiviral activity of membrane fusion inhibitors that target gp40 of the feline immunodeficiency virus envelope protein. Veterinary Microbiology, 2009, 136, 155-159.	1.9	9
115	Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. Antiviral Research, 2009, 82, 67-72.	4.1	25
116	Stromal cell–derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis and Rheumatism, 2009, 60, 813-823.	6.7	499
117	Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group. Bioorganic and Medicinal Chemistry, 2009, 17, 7964-7970.	3.0	11
118	Implanted Adult Human Dental Pulp Stem Cells Induce Endogenous Axon Guidance. Stem Cells, 2009, 27, 2229-2237.	3.2	144
119	Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency virus. Bioorganic and Medicinal Chemistry, 2009, 17, 4916-4920.	3.0	5
120	Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins. Bioorganic and Medicinal Chemistry, 2009, 17, 7487-7492.	3.0	8
121	Synthesis of Fluoroalkene Dipeptide Isosteres by an Intramolecular Redox Reaction Utilizing <i>N</i> -Heteorocyclic Carbenes (NHCs). Journal of Organic Chemistry, 2009, 74, 3272-3277.	3.2	33
122	Electrostatically constrained $\hat{l}\pm$ -helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. International Journal of Biochemistry and Cell Biology, 2009, 41, 891-899.	2.8	59
123	X-ray Crystallographic Study of an HIV-1 Fusion Inhibitor with the gp41 S138A Substitution. Journal of Molecular Biology, 2009, 392, 657-665.	4.2	15
124	Amino Acid-Based Synthesis of Trifluoromethylalkene Dipeptide Isosteres by Alcohol-Assisted Nucleophilic Trifluoromethylation and Organozincâ^'Copper-Mediated S _N 2′ Alkylation. Journal of Organic Chemistry, 2009, 74, 4626-4629.	3.2	18
125	Ring-Construction/Stereoselective Functionalization Cascade: Total Synthesis of Pachastrissamine (Jaspine B) through Palladium-Catalyzed Bis-cyclization of Bromoallenes. Organic Letters, 2009, 11, 4478-4481.	4.6	50
126	Construction of Nitrogen Heterocycles Bearing an Aminomethyl Group by Copper-Catalyzed Domino Three-Component Couplingâ^'Cyclization. Journal of Organic Chemistry, 2009, 74, 7052-7058.	3.2	106

#	Article	IF	CITATIONS
127	Palladium-Catalyzed Direct Synthesis of Carbazoles via One-Pot <i>N</i> -Arylation and Oxidative Biaryl Coupling: Synthesis and Mechanistic Study. Journal of Organic Chemistry, 2009, 74, 4720-4726.	3.2	149
128	Rapid Access to 3-(Aminomethyl)isoquinoline-Fused Polycyclic Compounds by Copper-Catalyzed Four-Component Coupling, Cascade Cyclization, and Oxidation. Journal of Organic Chemistry, 2009, 74, 6299-6302.	3.2	65
129	Facile Synthesis of 1,2,3,4-Tetrahydro-β-carbolines by One-Pot Domino Three-Component Indole Formation and Nucleophilic Cyclization. Organic Letters, 2009, 11, 1979-1982.	4.6	57
130	Cu(ii)-mediated oxidative intermolecular ortho C–H functionalisation using tetrahydropyrimidine as the directing group. Chemical Communications, 2009, , 3413.	4.1	48
131	Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres: synthesis and bioevaluation of α-helical anti-HIV peptide analogues. Organic and Biomolecular Chemistry, 2009, 7, 2872.	2.8	105
132	Structure-activity relationship study on artificial CXCR4 ligands possessing the cyclic pentapeptide scaffold: the exploration of amino acid residues of pentapeptides by substitutions of several aromatic amino acids. Organic and Biomolecular Chemistry, 2009, 7, 3805.	2.8	16
133	Efficient Synthesis of Aminomethylated Pyrroloindoles and Dipyrrolopyridines via Controlled Copper-Catalyzed Domino Multicomponent Coupling and Bis-cyclization. Journal of Organic Chemistry, 2009, 74, 4246-4251.	3.2	35
134	Inhibitory Effect of Newly Developed CXC-Chemokine Receptor 4 Antagonists on the Infection with Feline Immunodeficiency Virus. Journal of Veterinary Medical Science, 2009, 71, 121-124.	0.9	3
135	Synthesis and Application of (Z)-Alkene- and (E)-Fluoroalkene-Dipeptide Isosteres as cis-Amide Equivalents. Advances in Experimental Medicine and Biology, 2009, 611, 365-366.	1.6	1
136	Development of a Novel Fusion Inhibitor against T-20-resistant HIV-1. Advances in Experimental Medicine and Biology, 2009, 611, 389-391.	1.6	1
137	Development of Chemokine Receptor CXCR4 Antagonists Using Bio-mimetic Strategy. Advances in Experimental Medicine and Biology, 2009, 611, 145-146.	1.6	2
138	Synthesis and Application of Fluorescein―and Biotin‣abeled Molecular Probes for the Chemokine Receptor CXCR4. ChemBioChem, 2008, 9, 1154-1158.	2.6	39
139	Structureâ€Activity Relationships of Pyrazineâ€Based CK2 Inhibitors: Synthesis and Evaluation of 2,6â€Disubstituted Pyrazines and 4,6â€Disubstituted Pyrimidines. Archiv Der Pharmazie, 2008, 341, 554-561.	4.1	26
140	Structureâ€activity relationship study and NMR analysis of fluorobenzoyl pentapeptide GPR54 agonists. Biopolymers, 2008, 90, 503-511.	2.4	23
141	Identification of minimal sequence for HIV-1 fusion inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 9184-9187.	3.0	25
142	Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4124-4129.	2.2	29
143	Diastereoselective synthesis of highly functionalized fluoroalkene dipeptide isosteres and its application to Fmoc-based solid-phase synthesis of a cyclic pentapeptide mimetic. Tetrahedron, 2008, 64, 4332-4346.	1.9	54
144	Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41. Antiviral Research, 2008, 80, 71-76.	4.1	8

#	Article	IF	CITATIONS
145	Total Synthesis of (±)-Lysergic Acid, Lysergol, and Isolysergol by Palladium-Catalyzed Domino Cyclization of Amino Allenes Bearing a Bromoindolyl Group. Organic Letters, 2008, 10, 5239-5242.	4.6	89
146	Palladium-Catalyzed sp ³ C—H Activation of Simple Alkyl Groups: Direct Preparation of Indoline Derivatives from <i>N</i> -Alkyl-2-bromoanilines. Organic Letters, 2008, 10, 1759-1762.	4.6	193
147	Concise Synthesis of Indole-Fused 1,4-Diazepines through Copper(I)-Catalyzed Domino Three-Component Couplingâ"Cyclizationâ" <i>N</i> -Arylation under Microwave Irradiation. Organic Letters, 2008, 10, 3535-3538.	4.6	107
148	Structure-activity relationship study of CXCR4 antagonists bearing the cyclic pentapeptide scaffold: identification of the new pharmacophore. Organic and Biomolecular Chemistry, 2008, 6, 4374.	2.8	19
149	Palladium-catalysed biscyclisation of allenic bromoalkenes through a zipper-mode cascade. Chemical Communications, 2008, , 3534.	4.1	29
150	Facile synthesis of 3-(aminomethyl)isoquinolines by copper-catalysed domino four-component coupling and cyclisation. Chemical Communications, 2008, , 835.	4.1	48
151	Efficient Synthesis of Trifluoromethyl and Related Trisubstituted Alkene Dipeptide Isosteres by Palladium-Catalyzed Carbonylation of Amino Acid Derived Allylic Carbonates. Journal of Organic Chemistry, 2008, 73, 3942-3945.	3.2	29
152	Development of Novel G-Protein-Coupled Receptor 54 Agonists with Resistance to Degradation by Matrix Metalloproteinase. Journal of Medicinal Chemistry, 2008, 51, 7645-7649.	6.4	46
153	Direct Construction of Bicyclic Heterocycles by Palladium-Catalyzed Domino Cyclization of Propargyl Bromides. Organic Letters, 2008, 10, 1171-1174.	4.6	43
154	Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity. Journal of Medicinal Chemistry, 2008, 51, 388-391.	6.4	55
155	A future perspective on the development of chemokine receptor CXCR4 antagonists. Expert Opinion on Drug Discovery, 2008, 3, 1155-1166.	5.0	6
156	Stromal-Derived Factor 1 Signalling Regulates Radial and Tangential Migration in the Developing Cerebral Cortex. Developmental Neuroscience, 2008, 30, 117-131.	2.0	34
157	Heptad Repeat-Derived Peptides Block Protease-Mediated Direct Entry from the Cell Surface of Severe Acute Respiratory Syndrome Coronavirus but Not Entry via the Endosomal Pathway. Journal of Virology, 2008, 82, 588-592.	3.4	42
158	Development of Peptide-targeted Lipoplexes to CXCR4-expressing Rat Glioma Cells and Rat Proliferating Endothelial Cells. Molecular Therapy, 2008, 16, 516-524.	8.2	22
159	Blockade of CXCL12/CXCR4 Axis Ameliorates Murine Experimental Colitis. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 383-392.	2.5	80
160	Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists toward Downsizing. Perspectives in Medicinal Chemistry, 2008, 2, PMC.S422.	4.6	3
161	Direct Assessment of CXCR4 Mutant Conformations Reveals Complex Link between Receptor Structure and Gαi Activation. Journal of Biological Chemistry, 2007, 282, 5111-5115.	3.4	39
162	Development of Low Molecular Weight CXCR4 Antagonists by Exploratory Structural Tuning of Cyclic Tetra- and Pentapeptide-Scaffolds Towards the Treatment of HIV Infection, Cancer Metastasis and Rheumatoid Arthritis. Current Medicinal Chemistry, 2007, 14, 93-102.	2.4	41

#	Article	IF	CITATIONS
163	Inhibitors of the Chemokine Receptor CXCR4: Chemotherapy of AIDS, Metastatic Cancer, Leukemia and Rheumatoid Arthritis. Letters in Drug Design and Discovery, 2007, 4, 20-26.	0.7	1
164	Rapid hematopoietic progenitor mobilization by sulfated colominic acid. Biochemical and Biophysical Research Communications, 2007, 355, 970-975.	2.1	7
165	CXCR4 engagement promotes dendritic cell survival and maturation. Biochemical and Biophysical Research Communications, 2007, 361, 1012-1016.	2.1	43
166	CXCL12-CXCR4 Engagement Is Required for Migration of Cutaneous Dendritic Cells. American Journal of Pathology, 2007, 171, 1249-1257.	3.8	227
167	Design and synthesis of all diastereomers of cyclic pseudo-dipeptides as mimics of cyclic CXCR4 pentapeptide antagonists. Organic and Biomolecular Chemistry, 2007, 5, 1915.	2.8	24
168	Gold-Catalyzed Hydroarylation of Allenes:  A Highly Regioselective Carbonâ^'Carbon Bond Formation Producing Six-Membered Rings. Organic Letters, 2007, 9, 4821-4824.	4.6	123
169	One-pot synthesis of carbazoles by palladium-catalyzed N-arylation and oxidative coupling. Chemical Communications, 2007, , 4516.	4.1	122
170	Structureâ^'Activity Relationships of Cyclic Peptide-Based Chemokine Receptor CXCR4 Antagonists:Â Disclosing the Importance of Side-Chain and Backbone Functionalities. Journal of Medicinal Chemistry, 2007, 50, 192-198.	6.4	81
171	Facile Synthesis of Fluoroalkenes by Palladium-Catalyzed Reductive Defluorination of Allylic <i>gem</i> -Difluorides. Organic Letters, 2007, 9, 3465-3468.	4.6	89
172	SAR and QSAR Studies on the N-Terminally Acylated Pentapeptide Agonists for GPR54. Journal of Medicinal Chemistry, 2007, 50, 3222-3228.	6.4	29
173	Zipper-Mode Double Câ^'H Activation:  Palladium-Catalyzed Direct Construction of Highly-Fused Heterocyclic Systems. Organic Letters, 2007, 9, 4813-4815.	4.6	50
174	Bromoallenes as Allyl Dication Equivalents in the Presence or Absence of Palladium(0): Direct Construction of Bicyclic Sulfamides Containing Five- to Eight-membered Rings by Tandem Cyclization of Bromoallenes. Chemistry - A European Journal, 2007, 13, 1692-1708.	3.3	47
175	Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers, 2007, 88, 279-289.	2.4	50
176	Fmoc-based solid-phase synthesis of GPR54-agonistic pentapeptide derivatives containing alkene- and fluoroalkene-dipeptide isosteres. Biopolymers, 2007, 88, 272-278.	2.4	33
177	Direct Synthesis of 2-(Aminomethyl)indoles through Copper(I)-Catalyzed Domino Three-Component Coupling and Cyclization Reactions. Angewandte Chemie - International Edition, 2007, 46, 2295-2298.	13.8	145
178	Direct Synthesis of 2-(Aminomethyl)indoles through Copper(I)-Catalyzed Domino Three-Component Coupling and Cyclization Reactions. Angewandte Chemie - International Edition, 2007, 46, 3173-3173.	13.8	1
179	Versatile use of acid-catalyzed ring-opening of β-aziridinyl-α,β-enoates to stereoselective synthesis of peptidomimetics. Tetrahedron, 2007, 63, 9243-9254.	1.9	9
180	A Novel Oxazolidine Linker for the Synthesis of Peptide Aldehydes. International Journal of Peptide Research and Therapeutics, 2007, 13, 271-279.	1.9	11

#	Article	IF	CITATIONS
181	Screening and characterization of cyclic pentapeptide CXCR4 antagonists/inverse agonists using a pheromone responsive reporter gene in Saccharomyces cerevisiae: Utility of G protein coupled receptor constitutively active mutants. , 2007, , 61-77.		3
182	Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists Blood, 2007, 110, 537-537.	1.4	1
183	Cysteine-DerivedS-Protected Oxazolidinones:  Potential Chemical Devices for the Preparation of Peptide Thioesters. Organic Letters, 2006, 8, 467-470.	4.6	90
184	Stereoselective Synthesis of 3,6-Disubstituted-3,6-dihydropyridin-2-ones as Potential Diketopiperazine Mimetics Using Organocopper-Mediated anti-SN2â€~ Reactions and Their Use in the Preparation of Low-Molecule CXCR4 Antagonists. Journal of Organic Chemistry, 2006, 71, 3942-3951.	3.2	34
185	A novel one-pot reaction involving organocopper-mediated reduction/transmetalation/asymmetric alkylation, leading to the diastereoselective synthesis of functionalized (Z)-fluoroalkene dipeptide isosteres. Chemical Communications, 2006, , 4720.	4.1	27
186	Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. Organic and Biomolecular Chemistry, 2006, 4, 2354.	2.8	28
187	Unequivocal Synthesis of (Z)-Alkene and (E)-Fluoroalkene Dipeptide Isosteres To Probe Structural Requirements of the Peptide Transporter PEPT1. Organic Letters, 2006, 8, 613-616.	4.6	106
188	Potassium Carbonate-Promoted Stereospecific 5-Endo-TrigCyclization of Unactivated Allenes in the Absence of Any Transition Metals. Organic Letters, 2006, 8, 947-950.	4.6	47
189	Identification of a New Class of Low Molecular Weight Antagonists against the Chemokine Receptor CXCR4 Having the Dipicolylamineâ~'Zinc(II) Complex Structure. Journal of Medicinal Chemistry, 2006, 49, 3412-3415.	6.4	51
190	Synthesis of (Z)-Alkene and (E)-Fluoroalkene-Containing Diketopiperazine Mimetics Utilizing Organocopper-Mediated Reductionâ^'Alkylation and Diastereoselectivity Examination Using DFT Calculations. Journal of Organic Chemistry, 2006, 71, 4118-4129.	3.2	29
191	Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nuclear Medicine and Biology, 2006, 33, 489-494.	0.6	97
192	Stereoselective Synthesis of (Z)-Alkene-Containing Proline Dipeptide Mimetics. Journal of Organic Chemistry, 2006, 71, 4969-4979.	3.2	26
193	Involvement of the CXCL12/CXCR4 Pathway in the Recovery of Skin Following Burns. Journal of Investigative Dermatology, 2006, 126, 468-476.	0.7	120
194	Structure–activity relationship study on small peptidic GPR54 agonists. Bioorganic and Medicinal Chemistry, 2006, 14, 7595-7603.	3.0	45
195	Application of tri- and tetrasubstituted alkene dipeptide mimetics to conformational studies of cyclic RGD peptides. Tetrahedron, 2006, 62, 1416-1424.	1.9	38
196	Design and synthesis of downsized metastin (45–54) analogs with maintenance of high GPR54 agonistic activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 134-137.	2.2	64
197	The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases. Mini-Reviews in Medicinal Chemistry, 2006, 6, 989-995.	2.4	16
198	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood, 2005, 105, 931-939.	1.4	38

#	Article	IF	CITATIONS
199	Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood, 2005, 106, 1824-1830.	1.4	275
200	CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 2005, 24, 4462-4471.	5.9	249
201	Photolabile Protection for One-Pot Sequential Native Chemical Ligation. ChemBioChem, 2005, 6, 1983-1986.	2.6	38
202	A simple, Automated Quasi-4D-QSAR, Quasi-multi Way PLS Approach to Develop Highly Predictive QSAR Models for Highly Flexible CXCR4 Inhibitor Cyclic Pentapeptide Ligands Using Scripted Common Molecular Modeling Tools. QSAR and Combinatorial Science, 2005, 24, 620-630.	1.4	12
203	Development of Anti-HIV Agents Targeting Dynamic Supramolecular Mechanism: Entry and Fusion Inhibitors Based on CXCR4/CCR5 Antagonists and gp41-C34-Remodeling Peptides. Current HIV Research, 2005, 3, 289-301.	0.5	13
204	Kisspeptin-10-Induced Signaling of GPR54 Negatively Regulates Chemotactic Responses Mediated by CXCR4: a Potential Mechanism for the Metastasis Suppressor Activity of Kisspeptins. Cancer Research, 2005, 65, 10450-10456.	0.9	80
205	Elevated Serum Levels of Stromal-Derived Factor-1α Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients. Cancer Research, 2005, 65, 1700-1709.	0.9	186
206	The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opinion on Therapeutic Targets, 2005, 9, 1267-1282.	3.4	56
207	Mutations Conferring Resistance to Human Immunodeficiency Virus Type 1 Fusion Inhibitors Are Restricted by gp41 and Rev-Responsive Element Functions. Journal of Virology, 2005, 79, 764-770.	3.4	87
208	Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers. Journal of Biological Chemistry, 2005, 280, 9895-9903.	3.4	231
209	Stereoselective Synthesis of [l-Arg-l/d-3-(2-naphthyl)alanine]-Type (E)-Alkene Dipeptide Isosteres and Its Application to the Synthesis and Biological Evaluation of Pseudopeptide Analogues of the CXCR4 Antagonist FC131. Journal of Medicinal Chemistry, 2005, 48, 380-391.	6.4	99
210	Identification of Novel Low Molecular Weight CXCR4 Antagonists by Structural Tuning of Cyclic Tetrapeptide Scaffolds. Journal of Medicinal Chemistry, 2005, 48, 3280-3289.	6.4	85
211	Structure–activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Organic and Biomolecular Chemistry, 2005, 3, 4392.	2.8	31
212	Stromal cellâ€derived factor 1â€mediated CXCR4 signaling in rat and human cortical neural progenitor cells. Journal of Neuroscience Research, 2004, 76, 35-50.	2.9	153
213	Facile synthesis of membrane-embedded peptides utilizing lipid bilayer-assisted chemical ligationElectronic supplementary information (ESI) available: results of optimization of Ile-Cys ligation. Representative experimental procedure for the ligation. HPLC analyses of ligations of TMD 2 + 3 and TMD 6 + 7, and ISMS data of the resulting peptides. See	4.1	22
214	Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptidesElectronic supplementary information (ESI) available: experimental procedures, procedures of biological assays, Table S1: characterization data of novel synthetic compounds and HPLC chromatograms for 10E,10K and 10L. See http://www.rsc.org/suppdata/ob/b4/b401485p/. Organic	2.8	17
215	and Bomolecular Chemistry, 2004, 2, 1255. Sml2-Mediated Reduction of γ,Ĵ³-Difluoro-α,Ĵ²-enoates with Application to the Synthesis of Functionalized (Z)-Fluoroalkene-Type Dipeptide Isosteres. Journal of Organic Chemistry, 2004, 69, 1634-1645. 	3.2	89
216	Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Letters, 2004, 569, 99-104.	2.8	126

#	Article	IF	CITATIONS
217	Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2004, 315, 85-92.	2.1	115
218	CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Molecular Cancer Therapeutics, 2004, 3, 29-37.	4.1	87
219	Title is missing!. Angewandte Chemie, 2003, 115, 3373-3375.	2.0	15
220	Molecular-Size Reduction of a Potent CXCR4-Chemokine Antagonist Using Orthogonal Combination of Conformation- and Sequence-Based Libraries. Angewandte Chemie - International Edition, 2003, 42, 3251-3253.	13.8	189
221	Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene, 2003, 22, 8093-8101.	5.9	255
222	Reduction of Peptide Character of HIV Protease Inhibitors That Exhibit Nanomolar Potency against Multidrug Resistant HIV-1 Strains. Journal of Medicinal Chemistry, 2003, 46, 1764-1768.	6.4	43
223	Lipid Bilayer Simulations of CXCR4 with Inverse Agonists and Weak Partial Agonists. Journal of Biological Chemistry, 2003, 278, 47136-47144.	3.4	105
224	T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Letters, 2003, 550, 79-83.	2.8	252
225	bio-stable CXCR4 antagonistsElectronic supplementary information (ÉSI) available: Fig. S1: behaviors of TF14013, TF14016 and TF14013-Me in mouse serum; Fig. S2: behaviors of TF14002 (a), TF14005 (b), TF14006 (c) TF14013 (d), TF14016 (e) and TF14013 analogs (f) in rat liver homogenate; Table S1: characterization data Synthesis of bottent (CXCR4: inhibitions codes serving source to violate the service of the s), _{2.8}	95
226	T140 derivativesElectronic supplementary information (ESI) available: Fig. S1: behaviors of TE14005 (a), TE14011 and Ac-TE14011 (b) in mouse serum; Fig. S2: behaviors of TE14011 (a), Ac-TE14011 (b), TN14003 (c), Ac-TN14003 (d), TC14012 (e) and Ac-TC14012 (f) in rat liver homogenate; Table S1: characterization data of novel synthetic peptides; HPLC charts for synthetic compounds of TE14005, TE14011 and Ac-TE14.	2.8	61
227	Organic and Biomolecular Chemistry, 2003, 1, 3656. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opinion on Investigational Drugs, 2003, 12, 185-195.	4.1	56
228	Role of CXCR4 and SDF-1 in Mammary Tumor Metastasis in the Cat. Journal of Veterinary Medical Science, 2003, 65, 1069-1073.	0.9	13
229	CXCL12 expression by invasive trophoblasts induces the specific migration of CD16– human natural killer cells. Blood, 2003, 102, 1569-1577.	1.4	326
230	A Point Mutation That Confers Constitutive Activity to CXCR4 Reveals That T140 Is an Inverse Agonist and That AMD3100 and ALX40-4C Are Weak Partial Agonists. Journal of Biological Chemistry, 2002, 277, 24515-24521.	3.4	222
231	Diastereoselective Synthesis of r̃[(E)-CHCMe]- and r̃[(Z)-CHCMe]-Type Dipeptide Isosteres by Organocopper-Mediatedanti-SN2†Reaction. Organic Letters, 2002, 4, 1051-1054.	4.6	16
232	Diastereoselective Synthesis ofÏ^[(E)-CMeCH]- andÏ^[(E)-CMeCMe]- Type Dipeptide Isosteres Based on Organocopper-Mediatedanti-SN2â€~ Reaction. Organic Letters, 2002, 4, 1055-1058.	4.6	17
233	Diastereoselective Synthesis of Newl̈´[(E)-CHCMe]- andl̈´[(Z)-CHCMe]-type Alkene Dipeptide Isosteres by Organocopper Reagents and Application to Conformationally Restricted Cyclic RGD Peptidomimetics. Journal of Organic Chemistry, 2002, 67, 612-6173 Region and Streposelective triver for of chiral 13 - oxazolidin-2-one derivatives by organocopper	3.2	49
234	reagents provides novel access to di-, tri- and tetra-substituted alkene dipeptide isosteresElectronic supplementary information (ESI) available: synthetic procedures and characterization for 4a,b, 5a,b, 7b, 8a,b, 9a,b, 10b, 11a,b, 12b,c, 13b, 14a,b, 15, 16a,b, 17a,b, 18, 19b, 20b. See http://www.rsc.org/suppdata/p1/b2/b203482d/. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 1786-1793.	1.3	13

#	ARTICLE Remodeling of gp41-C34 Peptide Leads to Highly Effective Inhibitors of the Eusion of HIV-1 with Target	IF	CITATIONS
235	Cells We thank Dr. Terrence R. Burke, Jr., NCI, NIH, Frederick, MD 21702-1201, for proofreading the manuscript and providing useful comments. This research was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, Remodeling: Science Science and Technology, Japan,	2.0	10
236	Cells We thank Dr. Terrence R. Burke, Jr., NCI, NIH, Frederick, MD 21702-1201, for proofreading the manuscript and providing useful comments. This research was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Japan Society for the Promotion of Science, and the Japan Health Science Foundation Angewandte	13.8	157
237	Chemie International Edition 2002, 41, 2937 Certification of the Critical Importance of 1-3-(2-Naphthyl)alanine at Position 3 of a Specific CXCR4 Inhibitor, T140, Leads to an Exploratory Performance of Its Downsizing Study. Bioorganic and Medicinal Chemistry, 2002, 10, 1417-1426.	3.0	14
238	G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology, 2002, 3, 687-694.	14.5	1,215
239	Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: The insertion of an (E)-alkene dipeptide isostere into the βll′-turn moiety. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 923-928.	2.2	31
240	Stereoselective Synthesis of 2-Alkenylaziridines and 2-Alkenylazetidines by Palladium-Catalyzed Intramolecular Amination of α- and β-Amino Allenes. Journal of Organic Chemistry, 2001, 66, 4904-4914.	3.2	100
241	A Novel Synthetic Arg-Gly-Asp-Containing Peptide Cyclo(-RGDfî—»V-) Is the Potent Inhibitor of Angiogenesis. Biochemical and Biophysical Research Communications, 2001, 288, 711-717.	2.1	24
242	Stereoselective synthesis of a set of two functionalized (E)-alkene dipeptide isosteres of L-amino acid-L-Clu and L-amino acid-D-Clu. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 2445-2451.	1.3	18
243	Synthesis of (Z)-fluoroalkene dipeptide isosteres utilizing organocopper-mediated reduction of γ,γ-difluoro-α,β-enoates. Tetrahedron Letters, 2001, 42, 285-287.	1.4	44
244	New access to α-substituted (Z)-fluoroalkene dipeptide isosteres utilizing organocopper reagents under â€~reduction–oxidative alkylation (R–OA)' conditions. Tetrahedron Letters, 2001, 42, 5443-5446.	1.4	48
245	Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 359-362.	2.2	56
246	Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1897-1902.	2.2	115
247	Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation. Bioorganic and Medicinal Chemistry, 2001, 9, 2179-2187.	3.0	22
248	Biological and Genetic Characterization of a Human Immunodeficiency Virus Strain Resistant to CXCR4 Antagonist T134. AIDS Research and Human Retroviruses, 2001, 17, 615-622.	1.1	32
249	Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2633-2637.	2.2	114
250	Development of new methodology for the synthesis of functionalized α-fluorophosphonates and its practical application to the preparation of phosphopeptide mimetics. Chemical Communications, 2000, , 1081-1082.	4.1	35
251	Marked Increase in Anti-HIV Activity, as Well as Inhibitory Activity against HIV Entry Mediated by CXCR4, Linked to Enhancement of the Binding Ability of Tachyplesin Analogs to CXCR4. AIDS Research and Human Retroviruses, 1999, 15, 419-427.	1.1	44
252	Regiospecific ring-opening reactions of β-aziridinyl α,β-enoates with acids: application to the stereoselective synthesis of a couple of diastereoisomeric (E )-alkene dipeptide isosteres from a single β-aziridinyl α,β-enoate and to the convenient preparation of amino alcohols bearing α,β-unsaturated ester groups. Journal of the Chemical Society Perkin Transactions 1, 1999, , 2983-2996.	0.9	28

#	Article	IF	CITATIONS
253	Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 1999, 73, 7489-7496.	3.4	77
254	Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II). Bioorganic and Medicinal Chemistry, 1998, 6, 231-238.	3.0	56
255	Downsizing of an HIV–cell fusion inhibitor, T22 ([Tyr 5, 12 , Lys 7]-Polyphemusin II), with the maintenance of anti-HIV activity and solution structure 1. Bioorganic and Medicinal Chemistry, 1998, 6, 473-479.	3.0	25
256	Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr 5,12 , Lys 7) Tj ETQq0 0 0 Chemistry, 1998, 6, 1033-1041.	rgBT /Ove 3.0	erlock 10 Tf 50 68
257	Convenient one-pot synthesis of cystine-containing peptides using the trimethylsilyl chloride–dimethyl sulfoxide/trifluoroacetic acid system and its application to the synthesis of bifunctional anti-HIV compounds 1. Journal of the Chemical Society Perkin Transactions 1, 1998, , 495-500.	0.9	19
258	A Low-Molecular-Weight Inhibitor against the Chemokine Receptor CXCR4: A Strong Anti-HIV Peptide T140. Biochemical and Biophysical Research Communications, 1998, 253, 877-882.	2.1	297
259	A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection. Journal of Experimental Medicine, 1997, 186, 1389-1393.	8.5	391
260	Involvement of cholinergic processes in cholecystokinin (CCK) release by luminal oleic acid. Journal of the Autonomic Nervous System, 1997, 63, 179-182.	1.9	13
261	Effects of structural modulation on biological activity of bombesin analogues with (E)-alkene bond. Life Sciences, 1996, 60, 29-34.	4.3	16
262	Molecular Size of an Anti-HIV Peptide, T22, Can Be Reduced without Loss of the Activity. Chemistry Letters, 1996, 25, 571-572.	1.3	7
263	Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), with gp 120 and CD4 by surface plasmon resonance. BBA - Proteins and Proteomics, 1996, 1298, 37-44.	2.1	25
264	Solution-Phase Synthesis of an Anti-human Immunodeficiency Virus Peptide, T22 ((Tyr5,12,) Tj ETQq0 0 0 rgBT / Trimethylsilyl Trifluoromethanesulfonate Deprotection Chemical and Pharmaceutical Bulletin, 1995, 43, 12-18	Overlock I 1.3	10 Tf 50 312 T 14
265	SN2′ Ring opening of aziridines bearing an α,β-unsaturated ester group with organocopper reagents. A new stereoselective synthetic route to (E)-alkene dipeptide isosteres. Journal of the Chemical Society Perkin Transactions 1, 1995, , 1359-1371.	0.9	46
266	A Novel Route to Diastereomerically Pure(E)-Alkene Dipeptide Isosteres fromβ-Aziridinyl-α,β-enoates by Treatment with Organocopper Reagents. Angewandte Chemie International Edition in English, 1994, 33, 652-654.	4.4	88
267	Molecular Parameters for the Anti-Human Immunodeficiency Virus Activity of T22 ((Tyr5,12,) Tj ETQq1 1 0.7843	14 ₁ gBT /0	Dverlock 10 Tr
268	A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. BBA - Proteins and Proteomics, 1993, 1163, 209-216.	2.1	97
269	Syn-SN2' pathway in the reaction of certain .gamma(mesyloxy) .alpha.,.betaenoates with RCu(CN)MgX.BF3 reagents. Importance of MgX and bulky R group upon the diastereoselectivity. Journal of Organic Chemistry, 1993, 58, 1207-1214.	3.2	53
270	Antimicrobial Activity and Conformation of Tachyplesin I and Its Analogs Chemical and Pharmaceutical Bulletin, 1993, 41, 978-980.	1.3	57

#	Article	IF	CITATIONS
271	A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). Biochemical and Biophysical Research Communications, 1992, 189, 845-850.	2.1	133
272	"Higher order―zinc cuprates involving lithium chloride: synthesis of (E)-alkene dipeptide isosteres free from reductive elimination products. Tetrahedron Letters, 1992, 33, 3783-3786.	1.4	5
273	A highly stereoselective synthesis of (E)-alkene dipeptide isosteres via organocyanocopper-Lewis acid mediation reaction. Journal of Organic Chemistry, 1991, 56, 4370-4382.	3.2	155
274	Interactions of an antimicrobial peptide, tachyplesin I, with lipid membranes. Biochimica Et Biophysica Acta - Biomembranes, 1991, 1070, 259-264.	2.6	73
275	Application of dimethylsulphoxide(DMSO) / trifluoroacetic acid(TFA) oxidation to the synthesis of cystine-containing peptide. Tetrahedron Letters, 1991, 32, 1223-1226.	1.4	82
276	Determination of absolute configuration of the alkyl group at the α-position in the acyclic α-alkyl-(E)-β,γ-enoates by circular dichroism. Tetrahedron: Asymmetry, 1990, 1, 389-394.	1.8	11
277	Highly Selective Synthesis of(E)-Alkene Isosteric Dipeptides With High Optical Purity via RCu(CN)Li·BF3 Mediated Reaction. Angewandte Chemie International Edition in English, 1990, 29, 801-803.	4.4	40
278	Hochselektive Synthese von Dipeptidâ€isosteren (<i>E</i>)â€Alkenen hoher optischer Reinheit mit RCu(CN)Li·BF ₃ . Angewandte Chemie, 1990, 102, 816-818.	2.0	4
279	Studies on peptides. CLXVIII. Syntheses of three peptides isolated from horseshoe crab hemocytes, tachyplesin I, tachyplesin II, and polyphemusin I Chemical and Pharmaceutical Bulletin, 1989, 37, 2661-2664.	1.3	35
280	Combination of a new amide-precursor reagent and trimethylsilyl bromide deprotection for the Fmoc-based solid phase synthesis of human pancreastatin and one of its fragments (Fmoc =) Tj ETQq0 0 0 rgBT	/Ovædock	101 F 50 377

281Studies on peptides. CLV. Evaluation of trimethylsilyl bromide as a hard-acid deprotecting reagent in
peptide synthesis.. Chemical and Pharmaceutical Bulletin, 1987, 35, 3880-3883.1.3115